A Multi-Pathway Model We can think of this as a convergence of several mechanisms: L-cell activation from viral or microbial sensing Vagal signaling altered by cytokine release Gut-brain axis dysregulation, mirroring GLP-1 agonist effects Delayed motility from enteric nervous system inflammation Together, these pathways could produce a temporary GLP-1-like state during and shortly after the viral illness
Other phenomena seen in rapid withdrawal are psychotic symptoms, severe confusion and delirium, but again these hardly ever occur with slow dosage tapering
This FDA-approved weight loss injection operates by activating two receptor pathwaysGLP-1 and GIPsimultaneously
References [1] National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050 PubMed pubmed.ncbi.nlm.nih.gov [2] Worldwide trends in childhood overweight and obesity over the last 20 years PubMed pubmed.ncbi.nlm.nih.gov [3] National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 19902021, and forecasts up to 2050 ScienceDirect [4] Pediatric obesity
